Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jun 9;14(12):4069.
doi: 10.3390/jcm14124069.

Treatment Modalities for Angina with Non-Obstructive Coronary Arteries (ANOCA): A Systematic Review and Meta-Analysis

Affiliations
Review

Treatment Modalities for Angina with Non-Obstructive Coronary Arteries (ANOCA): A Systematic Review and Meta-Analysis

Fabienne E Vervaat et al. J Clin Med. .

Abstract

Background and Objectives: Up to 40% of patients undergoing a coronary angiogram due to angina pectoris have no obstructive coronary artery disease, also known as angina with non-obstructive coronary arteries (ANOCA). ANOCA is associated with significant impairment in patients' quality of life, increased risk of myocardial infarction and all-cause mortality. Approximately 25% of patients with ANOCA have persisting symptoms despite optimal medical therapy. There is a lack of in-depth knowledge regarding tailored treatment for patients with ANOCA due to a scarcity of trials designed to assess the effect of treatment modalities. The aim of this systematic review and meta-analysis is to give clinicians an overview of the efficacy of current treatment modalities for patients with ANOCA. Methods: PudMed/MEDLINE, Embase, the Cochrane Library and clinical trial registries were searched for randomised controlled and cohort studies regarding treatment modalities for ANOCA. The main outcome was change in angina pectoris frequency for each treatment modality. Secondary outcomes included changes in exercise capacity, quality of life, Canadian Cardiovascular Society (CCS) class, coronary flow reserve (CFR) and survival. Results: In total, 80 studies were included and used in the meta-analysis, of which ten studies met the current definition of ANOCA. Angina pectoris frequency improved significantly in the majority of the treatment modalities, with neuromodulation resulting in -3.35 standardised mean difference (SMD) (95% CI: -5.13; -1.56), trimetazidine in -1.74 SMD (-2.63; -0.85), traditional Chinese medicine in -1.55 SMD (-2.36; -0.75), beta-blockers in -1.32 SMD (-1.88; -0.77), enhanced external counterpulsation in -1.27 SMD (-2.04; -0.49), stem cell therapy in -1.04 SMD (-1.51; -0.57), lifestyle interventions in -0.86 SMD (-1.15; -0.57), RAAS-inhibitors in -0.83 SMD (-1.31; -0.35) and calcium channel blockers in -0.64 SMD (-0.92; -0.35). Conclusions: This meta-analysis into treatment modalities for patients with ANOCA shows a significant improvement in angina pectoris frequency in the majority of included treatment modalities. However, these results should be interpreted cautiously, as only ten of the studies included in the meta-analysis meet the current definition of ANOCA. This review underlines the importance of undertaking new studies with existing treatment modalities to determine the efficacy in patients with ANOCA.

Keywords: angina with non-obstructive coronary arteries (ANOCA); meta-analysis; treatment modalities.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
PRISMA flowchart.
Figure 2
Figure 2
Pooled estimate of the treatment effect on angina pectoris frequency per treatment modality.
Figure 3
Figure 3
Pooled estimate of the treatment effect on exercise capacity per treatment modality.
Figure 4
Figure 4
Pooled estimate of the treatment effect on quality of life per treatment modality.

Similar articles

References

    1. Patel M.R., Peterson E.D., Dai D., Brennan J.M., Redberg R.F., Anderson H.V., Brindis R.G., Douglas P.S. Low diagnostic yield of elective coronary angiography. N. Engl. J. Med. 2010;362:886–895. doi: 10.1056/NEJMoa0907272. - DOI - PMC - PubMed
    1. Jansen T.P.J., Konst R.E., de Vos A., Paradies V., Teerenstra S., van den Oord S.C.H., Dimitriu-Leen A., Maas A.H.E.M., Smits P.C., Damman P., et al. Efficacy of Diltiazem to Improve Coronary Vasomotor Dysfunction in ANOCA. J. Am. Coll. Cardiol. Imaging. 2022;15:1473–1484. doi: 10.1016/j.jcmg.2022.03.012. - DOI - PubMed
    1. Kunadian V., Chieffo A., Camici P.G., Berry C., Escaned J., Maas A.H.E.M., Prescott E., Karam N., Appelman Y., Fraccaro C., et al. An EAPCI Expert Consensus Document on Ischaemia with Non-Obstructive Coronary Arteries in Collaboration with European Society of Cardiology Working Group on Coronary Pathophysiology & Microcirculation Endorsed by Coronary Vasomotor Disorders International Study Group. Eur. Heart J. 2020;41:3504–3520. - PMC - PubMed
    1. Maddox T.M., Stanislawski M.A., Grunwald G.K., Bradley S.M., Ho M., Tsai T.T., Patel M.R., Sandhu A., Valle J., Magid D.J., et al. Nonobstructive Coronary Artery Disease and Risk of Myocardial Infarction. JAMA. 2014;213:1754–1763. doi: 10.1001/jama.2014.14681. - DOI - PMC - PubMed
    1. Tavella R., Cutri N., Tucker G., Adams R., Spertus J., Beltrame J.F. Natural history of patients with insignificant coronary artery disease. Eur. Heart J. Qual. Care Clin. Outcomes. 2016;2:117–124. doi: 10.1093/ehjqcco/qcv034. - DOI - PubMed

LinkOut - more resources